Injectable Erythrocyte Gel Loaded with Bulleyaconitine A for the Treatment of Rheumatoid Arthritis

作者：Hao Chen, Bo Tian, Xiyao Fang, Jinyu Bai, Qingle Ma, Yue Zhang, Jialu Xu, Beilei Wang, Qin Fan, Ziying Fei, Huaxing Dai, Huajian Shan, Xiang Gao, Qirong Dong, Chao Wang, Xiaozhong Zhou · 发表于：ACS Biomaterials Science & Engineering · 年份：2021 · DOI：10.1021/acsbiomaterials.1c01175 · 被引用次数：14 · 研究领域：Pharmacological Effects of Natural Compounds、Natural product bioactivities and synthesis、Rheumatoid Arthritis Research and Therapies

Rheumatoid arthritis (RA) is a systemic autoimmune disease with clinical manifestations including joint cartilage, synovitis, and bone damage. Here we developed an injectable erythrocyte gel loaded with Bulleyaconitine A (BLA) for the treatment of RA and demonstrated its anti-inflammatory effects in vivo and in vitro . In vitro experiments showed that BLA could effectively down-regulate the expression of pro-inflammatory factor in activated macrophages through the nuclear factor-κB (NF-κB) pathway. In vivo experiments have shown that the injection of BLA@RBCs in the inflammatory joints of CIA mice increases the local concentration of BLA in a long time. Improved therapeutic outcomes and reduced toxicity of BLA are demonstrated in our work. Together, the developed BLA@RBCs drug delivery system provides an alternative strategy to treat RA joints and shows high potential in clinical RA treatment.